Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper –February 2019 ─ Vaccins antipneumococciques conjugués chez les nourrissons et les enfants de moins de 5 ans: note de synthèse de l’OMS – février 2019

World Health Organization = Organisation mondiale de la Santé.
Wkly. epidemiol. rec; 94(08): 85-103, 2019-02-22.
Artigo em Zh, Inglês | WHOLIS | ID: who-310970

Documentos relacionados

  1. Serotype-specific quantification of residual free polysaccharide in multivalent pneumococcal conjugate vaccines.
  2. Development of a novel flow cytometry method for detecting pneumococcal-specific B cells.
  3. Distinct baseline immune characteristics associated with responses to conjugated and unconjugated pneumococcal polysaccharide vaccines in older adults.
  4. [The surveillance analysis of the adverse events following immunization of the domestic 13-valent pneumococcal polysaccharide conjugate vaccine in Zhejiang Province].
  5. Vaccination of immune compromised children-an overview for physicians.
  6. Pneumococcal Surface Protein A: A Promising Candidate for the Next Generation of Pneumococcal Vaccines.
  7. Qualification and Clinical Validation of an Immunodiagnostic Assay for Detecting 11 Additional Streptococcus pneumoniae Serotype-specific Polysaccharides in Human Urine.
  8. Student pharmacists delivering academic detailing on adult pneumococcal vaccination to community pharmacists.
  9. Adult Pneumococcal Vaccination: A Review of Current Status and Challenges in Nigeria.
  10. The Pneumococcal Polysaccharide-Tetanus Toxin Native C-Fragment Conjugate Vaccine: The Carrier Effect and Immunogenicity.